SCHEDULE 13G/A: Biotechnology Value Funds Disclose Significant Stake in Verastem, Inc., Nearing 10% Ownership

A group of investment funds managed by Biotechnology Value Fund entities, including Mark N. Lampert, have disclosed a collective beneficial ownership of 9.99% in Verastem, Inc., primarily through common stock, convertible preferred stock, and warrants.

Summary

• As of December 31, 2024, a group of reporting persons, including Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), and Biotechnology Value Trading Fund OS LP, along with their general partners and affiliates, collectively beneficially owned 4,706,551 shares of Verastem, Inc. common stock.
• This aggregate ownership represents approximately 9.99% of Verastem's outstanding common stock.
• The beneficial ownership includes 1,000,000 shares of Series A Convertible Preferred Stock, convertible into 833,333 common shares, which are not currently limited by the 9.99% conversion blocker.
• The group also holds 2,500,000 Pre-Funded Warrants, exercisable for 2,500,000 common shares at an exercise price of $0.001 per share, though exercise is limited to 1,772,750 shares due to a 9.99% beneficial ownership blocker.
• Additionally, 2,500,000 Warrants, exercisable for 2,500,000 common shares at an exercise price of $3.50 per share, are held, but their exercise is entirely prohibited by a 9.99% beneficial ownership blocker.
• Individual beneficial ownership percentages include BVF at 6.0%, BVF2 at 3.8%, and Trading Fund OS at less than 1%.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.

Risks

• The ability to fully convert Series A Preferred Stock, and exercise Pre-Funded Warrants and Warrants is subject to a 9.99% beneficial ownership limitation, which currently prohibits the exercise of all Warrants and limits the exercise of Pre-Funded Warrants.

Future Outlook

The document does not provide any forward-looking statements or guidance from Verastem, Inc. or the reporting persons regarding the company's future operations or financial performance.

Industry Context

This filing indicates a significant investment by a specialized biotechnology investment fund group in Verastem, Inc., a company operating within the biotechnology sector. Such substantial stakes by institutional investors are common in the biotech industry, where long-term capital and strategic positioning are crucial.

Related Party Transactions

• The various Biotechnology Value Fund entities (BVF, BVF2, Trading Fund OS, BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc., and Mark N. Lampert) are related parties to each other, collectively reporting their beneficial ownership in Verastem, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake (9.99%) can influence market perception and potentially provide a degree of stability or scrutiny regarding the company's governance and strategic direction.

Key Dates

Keywords

Verastem Inc., Biotechnology Value Fund, SEC Schedule 13G, Beneficial Ownership, Common Stock, Convertible Preferred Stock, Warrants, Pre-Funded Warrants, Investment Fund, Biotechnology, Institutional Investor